William Blair Maintains UniQure NV(QURE.US) With Buy Rating

William Blair analyst Sami Corwin maintains $uniQure NV(QURE.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 37.2% and a total average return of -4.6% over the pas

Futu News00:32 · Ratings

Sector Update: Health Care Stocks Mixed Premarket Monday

Health care stocks were mixed premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was 0.3% higher and the iShares Biotechnology ETF (IBB) was down 0.2% recently. SpringWorks Therapeutics

MT NewswiresJul 1 21:13

UniQure: Genezen Will Enter Strategic Supply Agreements for UniQure's Clinical Portfolio and CSL's Comml HEMGENIX Pdt >QURE

UniQure: Genezen Will Enter Strategic Supply Agreements for UniQure's Clinical Portfolio and CSL's Comml HEMGENIX Pdt >QURE

Dow JonesJul 1 19:05

Genezen To Acquire UniQure's Commercial Gene Therapy Manufacturing Operations In Lexington, MA QURE

Genezen To Acquire UniQure's Commercial Gene Therapy Manufacturing Operations In Lexington, MA QURE

Dow JonesJul 1 19:05

UniQure Shares Rise After US FDA Grants Regenerative Medicine Advanced Designation for Huntington's Treatment

uniQure (QURE) shares rose 8% in recent Monday trading after the company obtained the regenerative medicine advanced therapy designation from the US Food and Drug Administration for AMT-130 to treat H

MT NewswiresJun 3 22:59

UniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease

~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington's disease ~ ~ Receiving

GlobeNewswireJun 3 19:05